PF-543 (Citrate)
- Product NamePF-543 (Citrate)
- CAS1415562-83-2
- CBNumberCB12645149
- MFC33H39NO11S
- MW657.73
- MDL NumberMFCD23098795
- MOL File1415562-83-2.mol
Chemical Properties
| form | Powder |
| color | White to yellow |
PF-543 (Citrate) Chemical Properties,Usage,Production
Uses
PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 Citrate is >100-fold selectivity for SPHK1 over SPHK2. PF-543 Citrate is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 Citrate induces apoptosis, necrosis, and autophagy[1][2][3].in vivo
PF-543 (1 mg/kg; intraperitoneal injection; every second day; for 21 days; female C57BL/6 J mice) treatment has no effect on vascular remodelling but reduces right ventricular hypertrophy. The protection involves a reduction in the expression of p53 and an increase in the expression of anti-oxidant nuclear factor Nrf-2[2].
Mice are initially dosed (ip) with 10 mg/kg or 30 mg/kg of PF-543 for 24 h and the T1/2 is 1.2 h in blood samples. Administration of 10 mg/kg PF-543 for 24 h to mice induces a decrease in SK1 expression in pulmonary vessels[2].
| Animal Model: | Female C57BL/6 J mice (7-12 week-old) with hypoxic-induced pulmonary arterial hypertension[2] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection; every second day; for 21 days |
| Result: | Reduced right ventricular hypertrophy. The protection involves a reduction in the expression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear factor Nrf-2. |
IC 50
SphK1References
[1] Schnute ME, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88. DOI:10.1042/BJ20111929[2] MacRitchie N, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016 Aug;28(8):946-55. DOI:10.1016/j.cellsig.2016.03.014
[3] Hamada M, et al. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017 Aug 14;3:17047. DOI:10.1038/cddiscovery.2017.47
PF-543 (Citrate) Suppliers
Global(48)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | 32430 | 58 | ||
| +1-781-999-5354; | support@targetmol.com | 38999 | 58 | ||
| 571-89925085 | sales@amadischem.com | 131884 | 58 | ||
| +86 13818785766 | candy@biochempartner.com | 751 | 50 | ||
| 15800340161 | info@zzsrm.com | 6528 | 58 | ||
| 021-55669583 18616258598 | sales@wheybio.com | 4394 | 58 | ||
| 021-50840550 | 471161314@qq.com | 6193 | 58 | ||
| 13917534498 | john.st@163.com | 2155 | 58 | ||
| 021-24209075 | SHYIJIEBIO@126.COM | 3510 | 58 | ||
| 021-61998551 13122364865 | 1509327812@qq.com | 9777 | 58 |